TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies.

Published in:

2017

By:

• Burris, Howard;
• Kurkjian, C.;
• Hart, L.;
• Pant, S.;
• Murphy, P.;
• Jones, S.;
• Neuwirth, R.;
• Patel, C.;
• Zohren, F.;
• Infante, J.;
• Burris, Howard A 3rd;
• Kurkjian, C D;
• Murphy, P B;
• Jones, S F;
• Patel, C G;
• Infante, J R

Publication type:

journal article